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Abstract
The energetic burden of continuously concentrating solutes against gradients along the tubule may 
render the kidney especially vulnerable to ischemia. Indeed, acute kidney injury (AKI) affects 3% 
of all hospitalized patients.1,2 Here we show that the mitochondrial biogenesis regulator, 
PGC1α,3,4 is a pivotal determinant of renal recovery from injury by regulating NAD biosynthesis. 
Following renal ischemia, PGC1α−/− mice developed local deficiency of the NAD precursor 
niacinamide (Nam), marked fat accumulation, and failure to re-establish normal function. 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#termsReprints and 
permissions information is available at www.nature.com/reprints.
Supplementary Information is linked to the online version of the paper at www.nature.com/nature.
AUTHOR CONTRIBUTIONS
MTT designed experiments, performed the breeding, genotyping, renal injury models, cellular studies, analyzed data, and wrote the 
manuscript. ZKZ and IES performed and analyzed histopathology, enzyme histochemistry, electron microscopy, and the human biopsy 
immunohistochemistry studies. AHB created LC-MS assays, measured metabolites for cellular experiments, and analyzed metabolic 
results. EVK and SAK performed microultrasounds and analyzed flow results. MKB analyzed raw RNA sequencing data. WK, CBC, 
and EPR performed metabolomics, follow-up metabolite measurements, and in vivo experiments with cisplatin and Nam. SMP 
designed the experiments, analyzed results, and wrote the manuscript with input from all authors.
The authors declare no competing financial interests.
HHS Public Access
Author manuscript
Nature. Author manuscript; available in PMC 2016 September 16.
Published in final edited form as:
Nature. 2016 March 24; 531(7595): 528–532. doi:10.1038/nature17184.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Remarkably, exogenous Nam improved local NAD levels, fat accumulation, and renal function in 
post-ischemic PGC1α−/− mice. Inducible tubular transgenic mice (iNephPGC1α) recapitulated the 
effects of Nam supplementation, including more local NAD and less fat accumulation with better 
renal function after ischemia. PGC1α coordinately upregulated the enzymes that synthesize NAD 
de novo from amino acids whereas PGC1α deficiency or AKI attenuated the de novo pathway. 
Nam enhanced NAD via the enzyme NAMPT and augmented production of the fat breakdown 
product beta-hydroxybutyrate (β-OHB), leading to increased prostaglandin PGE2, a secreted 
autocoid that maintains renal function.5 Nam treatment reversed established ischemic AKI and 
also prevented AKI in an unrelated toxic model. Inhibition of β-OHB signaling or prostaglandins 
similarly abolished PGC1α-dependent renoprotection. Given the importance of mitochondrial 
health in aging and the function of metabolically active organs, the results implicate Nam and 
NAD as key effectors for achieving PGC1α-dependent stress resistance.
The mature renal tubule returns ~140L/day of filtered plasma water back to the circulation 
by establishing energy-intensive electrochemical gradients between the filtrate and 
vasculature. The kidney is only second to the heart in mitochondrial abundance.6 We 
hypothesized that PGC1α (peroxisome proliferator activated receptor gamma co-activator-1-
alpha), enriched in renal tubules and important for stress resistance in the brain, heart and 
other metabolically active organs,4,7–9 regulates oxidative metabolism in the epithelium to 
affect overall kidney health.
Hans Krebs identified acylglycerols as a major renal fuel.7 Following transient local 
ischemia, renal function worsened, PGC1α expression declined, tubular mitochondria 
swelled, and a pronounced accumulation of acylglycerols developed in tubules (p < 0.0001, 
Fig 1a–e, Extended Data 1a–c). The fidelity of serum creatinine was confirmed by 
comparison to cystatin C and inulin clearance (Extended Data 1d–f). PGC1α−/− mice 
experienced worse renal function, greater fat accumulation, and more tubular injury 
following ischemia (Fig 1f, Extended Data 2a–g). To define pathways specific to PGC1α 
altered by ischemia, we examined metabolite profiles. Comparing sham vs. post-ischemic 
kidneys yielded six differentially abundant metabolites; comparing uninjured PGC1α−/− vs. 
wildtype littermate kidneys yielded 11. Four were shared between settings, with all four 
lower in PGC1α−/− and post-ischemic kidneys (Fig 1g,h, Extended Data 3a,b).
Of these, carnitine deficiency in PGC1α−/− and post-ischemic kidneys supported 
mitochondrial involvement in both situations. Deficiency of betaine and choline, two 
osmolytes essential for cell volume maintenance in the uniquely hypertonic renal 
environment, was not unanticipated. We therefore focused on niacinamide (Nam), the 
predominant mammalian precursor to synthesize the energy carrier NAD needed for fatty 
acid oxidation (FAO).8 After confirming the metabolomics results (Extended Data 3c–e), we 
tested the effect of Nam supplementation. Exogenous Nam increased renal Nam (p < 0.001), 
normalized post-ischemic fat accumulation, and completely prevented post-ischemic AKI in 
PGC1α−/− mice (Fig 1i, Extended Data 3f–h), implicating this metabolite as an unexpected 
effector of PGC1α.
To probe the robustness of PGC1α’s relation to Nam, fat accumulation, and renal function, 
we developed an inducible tubular epithelial transgenic model using the well-validated Pax8 
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promoter (iNephPGC1α).9 Heterologous PGC1α was tightly controlled without leaky gene 
expression; organ size and mass were indistinguishable; and mitochondrial abundance 
increased—as assessed by comparing mitochondrial to nuclear DNA and mitochondrial gene 
products to cytosolic gene products—without altering ultrastructural morphology or the 
anatomical distribution favoring cortex and outer stripe of the outer medulla (Fig 2a–c, 
Extended Data 4a–i). iNephPGC1α mice tolerated renal ischemia more successfully, 
achieving better survival (p = 0.0039), more preserved function (p < 0.0001), better kidney 
perfusion, and less tubular injury (Fig 2d–k, Extended Data 4j,k). Sham-operated mice 
experienced no significant change in creatinine or reduced survival. Renal Nam was higher 
in post-ischemic iNephPGC1α mice, and post-ischemic fat accumulation was markedly 
reduced compared to controls (p < 0.0001, Fig 2l–q). Renal protection in iNephPGC1α mice 
was shared across distinct models as post-inflammatory renal injury was also attenuated 
(Extended Data 5a). PGC1α’s effect appeared to be cell-type specific as endothelial over-
expression conferred no renoprotection (Extended Data 5b).
RNA sequencing identified 1160 transcripts associated with PGC1α-dependent 
renoprotection (Fig 3a, Supplementary Information Table 1). The pathways most over-
represented related to intermediary metabolism (Fig 3b). Closer examination revealed that 
de novo NAD biosynthetic enzymes were coordinately regulated, induced in uninjured 
iNephPGC1α kidneys and suppressed in post-ischemic or uninjured PGC1α−/− kidneys (Fig 
3c–f). PGC1α’s effect on the de novo pathway was cell- autonomous as knockdown in 
isolated renal tubular cells was sufficient to suppress the pathway (p = 0.0001, Extended 
Data 6a).
As epithelial PGC1α defended renal function and resolved post-ischemic fat accumulation, 
we hypothesized that protection from AKI may relate to Nam, NAD, and fatty acid 
utilization. Indeed, exogenous Nam dose-dependently increased renal NAD and drove local 
accumulation of the fatty acid breakdown product β-OHB to ~ten-fold higher than normal 
circulating concentrations (p < 0.0001, Fig 3g and Extended Data 6b,c). β-OHB activates 
HCAR2, a G-protein coupled receptor that induces the renoprotective prostaglandin 
PGE2.5,15 Silencing or chemical inhibition of HCAR2 markedly reduced both basal and 
ligand-dependent PGE2 secretion (Fig 3h, Extended Data 6d,e). Nam augmented PGE2 
secretion, requiring conversion to NAD via the enzyme NAMPT to do so (Fig 3i, Extended 
Data 6f,g).10 Silencing of PGC1α reduced each intermediate, lowering the cellular NAD and 
secreted β-OHB and PGE2 (Fig 3j–l). In PGC1α-silenced cells, excess β-OHB was still able 
to induce PGE2 secretion (p < 0.0001, Extended Data 6h). Finally, renal levels of each 
component mirrored the cellular results, with opposing effects of PGC1α deficiency and 
excess on NAD, β-OHB, and PGE2 (Fig 3m–o, Extended Data 7a–c). Together, these results 
implicated PGC1α-dependent NAD production as an important determinant of cellular 
metabolism that induces renoprotective molecules (Fig 3p).
To test this further, we inhibited β-OHB signaling with mepenzolate bromide or 
prostaglandin synthesis with indomethacin in iNephPGC1α mice subjected to ischemia. 
Renal protection was similarly abolished in either setting, confirming their roles as PGC1α 
effectors (Fig 4a,b, Extended Data 7d,e). Since Nam prevented ischemic AKI in PGC1α−/− 
mice, we then asked whether Nam has a broader therapeutic role. Nam administered after 
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established AKI significantly improved renal function (p = 0.0011, Fig 4c). We also 
observed that renal Nam declined following cisplatin, a chemotherapy whose use is limited 
by nephrotoxicity and whose injurious mechanism involves mitochondria but is considered 
distinct from ischemia (Extended Data 7f,g). Nam supplementation prevented cisplatin-
induced AKI (Fig 4d,e). Finally, we found that PGC1α expression in human AKI was 
strongly suppressed, even in histologically normal regions of renal tissue (Fig 4f–h, 
Extended Data 8a–f), mirroring the AKI-induced suppression of PGC1α observed in 
experimental models (Extended Data 1c and 11). These results show that PGC1α is a 
negatively regulated target in AKI.
The present results identify PGC1α as a pivotal mediator of renal resistance to acute 
stressors. By linking oxidative metabolism in the epithelium to overall organ function, the 
proposed pathway provides new insight into a longstanding observation, namely the 
exquisite sensitivity of the kidney to ischemia and other insults. More fundamentally, the 
results implicate NAD biosynthesis as a coordinately regulated target of PGC1α.
NAD has long been recognized for its central role in energy metabolism, with recent work 
demonstrating that NAD is rate-limiting for mitochondrial function.12 NAD augmentation 
appears to restore youthful mitochondrial function and reverse age-related declines in 
health.13 In contrast, NAD depletion has been described as a feature of diabetes.14 Since 
diabetes and aging are two of the most prevalent predispositions for AKI, the present results 
motivate interest in whether local NAD concentration may provide a setpoint for resistance 
to acute renal stressors. NAD may also be important for the gradual decline of kidney 
function with normal aging.
That an even larger set of known AKI risk factors—including diabetes, but also chronic 
kidney disease (Extended Data 8g,h), sepsis, and warm ischemia—is associated with 
reduction of PGC1α,11,15 further attests to the potential relevance of the results to human 
disease. Experiments targeting mitochondrial biogenesis through a drug-screening approach 
offer additional promise for this avenue in AKI.16 Since AKI has been associated with death 
in critically ill patients,1 that excess renal PGC1α improves survival after AKI highlights the 
importance of the kidney to overall health. Downstream of PGC1α, Nam may not only be an 
effective preventative agent, but also a potential therapy for established AKI, a set of 
diseases for which no drug has yet been identified.
PGC1α in skeletal muscle has been shown to exert extracellular effects, whether through the 
myokine irisin, metabolites such as kynurenine, or the angiogenic factor VEGF.17–19 By 
comparison, the present results show that renal tubular PGC1α communicates with 
neighboring cells at least through PGE2. Therapeutic manipulation of renal β-OHB may 
constitute one means of increasing PGE2. PGE2 is a well-recognized vasodilator in the 
kidney, but may also be exerting cytoprotective effects in AKI (reviewed in 20), actions that 
have been demonstrated in multiple animal models and even humans.21–23
We observed enhanced renal function, vascular relaxation, and increased perfusion at 
baseline as a result of excess PGC1α in the epithelial compartment of the kidney in the 
iNephPGC1α model (Extended Data 9a–j), physiological features that would be consistent 
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with functional responses of the local vasculature to the excess renal PGE2 present in this 
model. However, we also asked whether VEGF was regulated by renal PGC1α as such 
features could also arise from increased vascularization (Extended Data 9k–m). PGC1α−/− 
mice showed no decrement in renal VEGF and iNephPGC1α mice displayed only modest 
induction vs. their respective controls. This strongly contrasts with VEGF induction by 
skeletal muscle PGC1α,17 suggesting the presence of cell-specific modulators of PGC1α 
function such as ERRα, which is notably more abundant in skeletal muscle than kidney 
(www.biogps.org).
Our results suggest several avenues for future investigation. First, the coordinated regulation 
of NAD biosynthesis by PGC1α may occur in other cells and organs, particularly under 
stress conditions. Of the major biosynthetic routes to NAD—de novo from amino acids, the 
Preiss-Handler pathway from niacin, and salvage from Nam via NAMPT—PGC1α’s action 
on each will require careful dissection as this may vary depending on cell type and 
condition. The transcription factor(s) with which PGC1α interacts to induce the de novo 
pathway are of substantial interest. Since ischemia did not reduce renal NAMPT (Extended 
Data 10), the salvage pathway may be a viable therapeutic route. Second, the rapid reduction 
of NAD during AKI may also relate to its already short half-life24 as well as the action of 
NAD-consuming enzymes such as PARPs, nucleotidases, and sirtuins, all of which have 
been implicated in this condition.25–27 Third, NAD’s emerging role as a guardian against 
age-related decline in health and mitochondrial function13 suggests that therapeutic 
manipulation of Nam and NAD may have implications beyond AKI. For example, NAMPT 
agonism protects against experimental neuronal injury.28 And inhibition of urinary Nam 
disposal (by blocking N-methylation) prevents experimental obesity.29 Finally, the link from 
mitochondrial metabolism to renoprotective prostaglandins unites two major avenues of 
mechanistic investigation in AKI, but other mediators and downstream effectors for renal 
PGC1α may also exist.
In summary, the present work applies complementary discovery approaches to identify a 
new pathway by which parenchymal PGC1α affects NAD to protect against renal injury. The 
results may have mechanistic, diagnostic, and therapeutic implications in the kidney and 
beyond.
 METHODS
 Mouse studies
All studies with mice were reviewed and approved by the Institutional Animal Use and Care 
Committee of Beth Israel Deaconess Medical Center (BIDMC). PGC1α−/− (stock # 
008597), Pax8-rtTA (# 007176) and TRE-PGC1α (# 012387) mice were all obtained from 
Jackson Laboratories and bred at BIDMC. The parental strains were generated on a mixed 
C57 background with further backcrossing into C57BL/6J as described by the manufacturer, 
except for the TRE-PGC1α mouse, which was generated on and is maintained on FVB. 
Primers for genotyping have been described elsewhere.30,31 All experiments were performed 
with littermate controls.
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Ischemia-reperfusion injury (IRI) was performed on 8–12 week-old males through two small 
paramedial dorsal incisions by applying a microvascular clamp to each renal pedicle for 20 
minutes. Mice were anesthetized with isoflurane for the duration of surgery and warmed to 
37°C using a servo-controlled heating pad. Incisions were closed in two layers and mice 
were revived with 1 ml warm saline injected intraperitoneally.
All chemicals were purchased from Sigma-Aldrich unless otherwise noted. Niacinamide was 
given by intraperitoneal injection of 400 mg/kg/day × 4 days in saline, with the final dose an 
hour prior to IRI surgery. In rescue experiments, the same dose was administered once 18 
hours after reperfusion. Indomethacin was given by intraperitoneal injection of 10 mg/kg in 
0.1 M sodium carbonate/saline an hour prior to IRI. The HCAR2 inhibitor, mepenzolate 
bromide, was given by intraperitoneal injection of 10 mg/kg in saline an hour prior to 
IRI.32–34 LPS (E.coli serotype O111:B4) was given by intraperitoneal injection of 25 mg/kg 
in saline. Cisplatin was given by intraperitoneal injection of 25 mg/kg as previously 
described.35 Unless otherwise stated, blood and kidneys were collected 24 h after the AKI 
model.
 Mass spectrometry measurements
All measurements were performed in a blinded fashion by an independent facility. 
Creatinine was analyzed by LC/MS-MS at the University of Alabama Birmingham O’Brien 
Core Center for Acute Kidney Injury Research (NIH P30-DK079337). This method adds the 
accuracy of MS to the LC method of creatinine measurement endorsed by a renal 
investigative consortium (diacomp.org). The coefficient of variation was 6% indicating high 
assay precision.
For metabolomics measurements, snap frozen kidneys were cut to equal weights (20 mg/
specimen) and mechanically homogenized into 4 volumes of ice-cold water. Metabolites 
were assayed as previously described.36 In brief, amino acids, amines, acylcarnitines, 
nucleotides, and other cationic polar metabolites were measured in 10 μl of kidney 
homogenate using hydrophilic interaction liquid chromatography coupled with nontargeted, 
positive ion mode MS analysis on an Exactive Plus Orbitrap MS (Thermo Scientific). Polar 
and non-polar lipids were measured in 10 μl of kidney homogenate using C8 
chromatography and nontargeted, positive ion mode MS analysis on a Q Exactive MS 
(Thermo Scientific). Identification of known metabolites was achieved by matching 
retention times and mass-to-charge ratio (m/z) to synthetic mixtures of reference compounds 
and characterized pooled plasma reference samples. Results were analyzed in 
MetaboAnalyst (www.metaboanalyst.ca).
LC-MS assays were developed for multiplex quantification of Nam, NAD, and β-
hydroxybutyrate (β-OHB) from cellular experiments. NAD measurements reflect total 
NAD+ plus NADH. Briefly, conditioned medium was extracted with methanol (80% 
methanol final concentration) spiked with isotopic standards for Nam and β-OHB (CDN 
Isotopes, Inc.). Precipitated proteins were removed by centrifugation, and supernatants were 
analyzed directly. For analysis of cell lysates, cells were washed with ice-cold PBS, scraped 
and lysed on dry ice into methanol containing isotopic standards. After extraction, cell and 
media supernatants were analyzed by LC-MS/MS using reverse-phase chromatography 
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(NAM and NAD/NADH) or hydrophilic interaction chromatography (β-OHB) coupled to 
tandem mass spectrometry using an API 5000 triple quadruple mass spectrometer. Analytes 
were quantified by multiple reaction monitoring using the following m/z transitions: β-OHB 
103.1>59, β-OHB IS 105.1>60, NAM 123.3>80.2, NAM IS 127.3>84.2, NAD/NADH 
664.2>542.0. Eluting peaks were quantified by area under the curve (AUC).
Raw AUC values were divided by the mean value of the control group for each experiment, 
thus the results are presented as relative concentrations to the control group. All assays were 
performed in triplicate and replicate measurements demonstrated a CV < 5%.
 RNASEQ sequencing and identification of differentially expressed transcripts
PolyA-enriched RNA was isolated from whole kidneys and checked for quality by 
denaturing agarose gel as well as Aglient Bioanalyzer. Sequencing libraries were generated 
from the double-stranded cDNA using the Illumina TruSeq kit according to the 
manufacturer’s protocol. Library quality control was checked using the Agilent DNA High 
Sensitivity Chip and qRT-PCR. High quality libraries were sequenced on an Illumina HiSeq 
2000. To achieve comprehensive coverage for each sample, we generated ~25–30 million 
single end reads. Raw results were passed through quality controls steps and aligned to the 
mouse genome. Gene expression measurement was performed from aligned reads by 
counting the unique reads. The read count based gene expression data was normalized on the 
basis of library complexity and gene variation. The normalized count data was compared 
among groups using a negative binomial model to identify differentially expressed genes. 
The differentially expressed genes were identified on the basis of raw P value and fold 
change. Genes were considered significantly differentially expressed if the multiple test 
corrected p-value was < 0.05 and absolute fold change > 2.
 Functional enrichment analysis
Ingenuity Pathway Analysis (IPA 8.0, Qiagen) was used to identify the functions that are 
significantly affected by significantly differentially expressed genes from different 
comparisons. The knowledge base of this software consists of functions, pathways, and 
network models derived by systematically exploring the peer reviewed scientific literature. A 
detailed description of IPA analysis is available at the Ingenuity Systems’ web site (http//
www.ingenuity.com). A p-value is calculated for each function according to the fit of the 
users’ data to the IPA database using one-tailed Fisher exact test. The functions with 
multiple test corrected p-values < 0.01 were considered significantly affected.
 Western analysis
Kidney lysate preparation, gel electrophoresis, transfer, immunoblotting, detection, and 
image acquisition were performed as previously described.30 Antibodies against PGC1α 
(Cayman Chemical), cytochrome c oxidase subunit IV (Cell Signaling Technology), and 
Transcription Factor A Mitochondrial, TFAM (Abcam) were used as previously 
described. 30,37
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 Quantitative PCR
Total RNA extraction and cDNA synthesis were performed as previously described.30 PCR 
reactions were performed in duplicate using the ABI 7500 Fast Real-Time PCR and TaqMan 
gene expression assays (Applied Biosystems). The following TaqMan gene probes were 
used: Ppargc1a, Ndufs1, Cycs, Atp5o, Nrf1, Tfam, Vegfa, Nos1, Nos3, Hcar2. Of the four 
known Ppargc1a transcripts (1–4), Ppargc1a1 (Taqman Mm00447183_m1) was studied in 
all gene expression analyses.38 Mouse Ido2, Afmid, Kynu, Kmo, Haao, Qprt, Naprt, and 
Nmnat1 for SYBR Green PCR have been described elsewhere.39,40 Mouse Nampt SYBR 
primers were designed using PrimerQuest Tool (Integrated DNA Technologies). Relative 
expression levels were determined using the comparative threshold method.
 Mitochondrial DNA copy number analysis
Total DNA was extracted from mouse kidneys using the DNeasy Blood and Tissue Kit 
(Qiagen) with on-column RNase digestion per manufacturer’s instructions. Gene expression 
of mitochondrial-encoded NADH dehydrogenase 1 (mt-Nd1) relative to nuclear 18S rRNA 
was used to determine mitochondrial DNA copy number as previously described.41
 Histopathology
Formalin-fixed, paraffin-embedded blocks were sectioned and stained with H & E, PAS, and 
Masson trichrome. Ten random high-power fields in the cortex and ten random high-power 
fields in the outer stripe of the outer medulla were viewed and graded for tubular necrosis—
defined as the loss of the proximal tubular brush border, blebbing of apical membranes, 
tubular necrosis/apoptosis and epithelial cell detachment from _the basement membrane or 
intraluminal aggregation of necrotic debris. Each high-power field was separately scored on 
a scale (0 = no necrosis, 1= rare single necrotic cells, 2= frequent single necrotic cells, 3 = 
groups of necrotic cells, and 4 = confluent tubular necrosis) and the average score was 
compiled for each specimen and then used for between-group comparisons. All scoring was 
performed by a single operator blinded to genotype and experimental model (IES).
 In situ COX enzyme chemistry
Enzyme histochemistry to detect cytochrome c oxidase (COX) activity was performed on 6 
μm snap-frozen sagittal sections as previously described.30 Functional electron microscopy 
used in the cisplatin kidney injury model was described earlier.35
 Electron microscopy
The complete method is previously described.30 Briefly, kidneys were fixed with 1.25% 
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) and cut in 1 μm section in both sagittal 
and transverse planes for image analysis. After drying the sections, slides were stained at 
65°C for 20 minutes in 0.1% Toluidine blue in 1% sodium borate, cooled to room 
temperature, washed in distilled water, cleaned in xylene, and mounted in Permount sections 
for light microscopy. Subsequent ultrathin sections (0.5 μm) were examined by transmission 
electron microscopy (JEOL 1011, JEOL Corp.) with Orca-HR Digital Camera (Hamamatsu 
Corp.), and Advanced Microscopy Technique Corporation image capture system.
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 Oil-Red-O staining
Oil-Red-O solution was prepared by dissolving 0.5 g Oil-Red-O (Poly Scientific) in 100 ml 
isopropanol. Frozen sections were cut to 5 μm and natively stained in Oil-Red-O solution for 
20 minutes at room temperature, then rinsed in running tap water for 2 min. Hematoxylin 
counter-staining was performed without differentiation in HCl-ethanol and sections were 
rinsed with water, then mounted with VectaMount AQ Aqueous Mounting medium (Vector 
Labs).
 Human biopsy series
All studies were approved by the Institutional Review Board at BIDMC. Control specimens 
came from normal tissue sections of nephrectomies. CKD diagnoses included focal 
segmental glomerulosclerosis, chronic allograft nephropathy, chronic interstitial nephritis, 
and chronic IgA nephropathy. AKI diagnoses included acute ischemic injury, post-transplant 
delayed graft function attributable to ischemia-reperfusion injury, and acute interstitial 
nephritis. PGC1α antibody (Abcam ab54481) was used at a dilution of 1:100 and developed 
with horseradish peroxidase (ImmPRESS polymer staining kit, Vector Labs). The peptide 
immunogen SKYDSLDFDSLLKEAQRSLRR (synthesized by the Biopolymers Lab, Koch 
Institute at MIT) was pre-incubated in 100-fold excess of the PGC1α antibody to confirm 
antibody specificity in human IHC studies. Ten randomly selected high-powered fields were 
viewed per specimen, with each field scored on a 4-point scale (1 = weakest, 4 = strongest) 
based on the intensity of staining, specifically in non-necrotic areas and unscarred areas and 
avoiding obvious collecting ducts. The average score of each specimen was then used for 
between-group comparisons. All scoring was performed by a single operator blinded to the 
underlying diagnosis (IES).
 Microultrasound
The full method is previously described.30 Briefly, mice were lightly anesthetized, secured 
to a heat-controlled stage, and continuously monitored for respiration, ECG, and core 
temperature. A high frequency, high resolution digital imaging platform with linear array 
technology and equipped with a high-frequency linear array probe MS550D (22–55 MHz) 
was used throughout the study (Vevo 2100 Visual Sonics). The flow volume was modeled as 
a circular cylinder of length equal to the average velocity time integral and diameter 
measured empirically (n = 3 cardiac cycles), then multiplied by the heart rate (bpm), then 
converted from mm3/min to ml/min. All measurements and analyses were performed by a 
single blinded operator (EVK).
 Cellular studies
Mouse intermedullary collecting duct (IMCD3) cells were obtained from ATCC. Please 
refer to their website for validation and mycoplasma testing. Cells were transfected with 
siRNA targeting mouse PGC1α, HCAR2 or a negative control siRNA (Qiagen) for 24 h. 
Niacin, mepenzolate bromide, β-hydroxybutyrate, the NAMPT inhibitor FK866,42 and 
niacinamide were diluted to the indicated concentrations in serum- free cell culture medium. 
Prostaglandin E2 (PGE2) was measured in the conditioned media 24–72 hours after 
treatment.
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 Cystatin C
Cystatin C in mouse serum (1:200 dilution) was measured by ELISA (R&D Systems).
 FITC-inulin clearance
The full method is described elsewhere.43 Briefly, male C57BL/6J mice (Jackson 
Laboratories) were given a single bolus injection of 5%-FITC- inulin (3.74 μl/g body 
weight). Clearance kinetics of FITC-inulin post-injection was measured by serial blood 
collection at specified time points from 3 through 70 minutes post-injection. Blood samples 
were centrifuged and resulting plasma was buffered to pH 7.4 with 500 mM HEPES. 
Fluorescence in the buffered plasma samples was determined with 485 nm excitation, 538 
nm emission. Glomerular filtration rate (GFR) was calculated from the two phase 
exponential decay model outlined previously.
 Tissue PGE2 β-OHB, and NAD measurements
PGE2 was measured in mouse kidney tissue by ELISA (Cayman Chemical). β-OHB 
(Cayman Chemical) and total NAD (BioVision) was measured in mouse kidney tissue by 
colorimetric assays. These assays were performed on kidneys used for metabolomics and 
lipidomics in order to compare coordinated changes in metabolism and downstream 
signaling. NAD measurements reflect total NAD+ plus NADH.
 Statistical Analysis
Comparisons between continuous characteristics of subject groups were analyzed with 
Mann-Whitney U tests or Student’s t test. Survival was analyzed by log-rank test. For 
comparisons among more than two groups, ANOVA with Bonferroni correction was used 
where indicated. Associations between microultrasound measurements and other functional 
parameters were analyzed with Spearman’s rank correlation coefficients. Sample size 
determination was guided by power calculations and prior experience. The following sample 
calculation was used to guide creatinine studies in mice: serum creatinine of 1.6 (± 0.3 SD) 
mg/dl vs. 1.0 (± 0.2 SD) requires n = 5 mice per condition to achieve an α-error < 5% and 
power 96%. Mice were randomized to experimental intervention vs. control. Two-tailed p-
values < 0.05 were considered significant. Results are presented as mean ± SEM and were 
prepared in GraphPad Prism.
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 Extended Data
Extended Data Fig 1. Regulation of PGC1α and other features of post-ischemic kidneys
a, Serum creatinine 24 h after sham or IRI (n=5 vs. 14 mice), ***p< 0.001. b, Absence of 
classwide changes in intrarenal phospholipids 24 h after IRI vs. sham operation (n=6/group, 
NS=non-significant). Each bar represents one lipid species. P-value by two-way ANOVA. c, 
Renal PGC1α expression 24 h after sham or IRI (n = 5 animals per group), **p<0.01. d, 
Correlation of LC-MS method for serum creatinine and serum cystatin C (measured by 
ELISA). e, Glomerular filtration rate in controls or 24 h after IRI was determined by two-
phase exponential decay curves of fluorescently-labeled inulin as described in methods 
(n=5/group), *p<0.05. f, Correlation of LC-MS method for serum creatinine with clearance 
of FITC-inulin. Curve fit according to formula sCr=κ/GFR where κ is a constant. Error bars 
SEM.
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Extended Data Fig 2. Exacerbation of fat accumulation and tubular injury in post-ischemic 
PGC1α−/− kidneys
a–d, Low (a,b) and high-power (c,d) photomicrographs 24 h after IRI in WT vs. PGC1α−/− 
(KO) mice. Scale bars 100 and 50 μm. e,f, Blinded scoring of tubular injury in cortex and 
outer stripe of outer medulla (OSOM) on 4-point injury scale as described in Methods (n=8 
WT vs.12 KO mice), *p<0.05. g, Di-/tri-acylglycerols (DAGs, TAGs) in renal homogenates 
of KO mice at baseline and 24 h after injury (n=6/group). Each bar represents one lipid 
species. P-value by two-way ANOVA. Error bars SEM.
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Extended Data Fig 3. Niacinamide (Nam) reduction from IRI and PGC1α deficiency
a, Heatmaps (red=higher, green=lower) of Bonferroni-corrected significantly different 
metabolites in sham vs. IRI kidneys and WT vs. KO kidneys. Metabolites listed in purple are 
shared between settings. b, Total ion chromatogram of polar, positive ion mode method for 
representative WT-IRI sample, with niacinamide (Nam) peak at retention time = 3.88 
minutes. Inset shows representative niacinamide peaks for kidney extracts from WT control 
(Ctrl) and WT-IRI (IRI) mice. c–e, Relative renal Nam abundance in kidneys of KO mice vs. 
WT littermates; WT littermates at baseline and 24 h after IRI; and KO mice at baseline and 
24 h after IRI (n=6/group). f, Relative renal Nam concentrations in kidneys of mice 
following vehicle (Veh) vs. Nam treatment (400 mg/kg IP × 4d) with and without IRI 24 h 
prior to tissue collection (n=6/group). P-values by two-way ANOVA. g,h, Oil Red O stain 
(pink) for fat accumulation 24 h after IRI with or without Nam pretreatment (400 mg/kg IP 
× 4 d), scale bar 20 μm. Error bars SEM, *p<0.05, **p<0.01, ***p<0.001.
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Extended Data Fig 4. Increased mitochondrial abundance and post-ischemic protection in renal 
tubular epithelial transgenic mice (iNephPGC1α)
a, Schematic for generating iNephPGC1α mice. b, Relative renal PGC1α expression in 
controls vs. iNephPGC1α mice with and without 4 weeks of doxycycline in drinking water 
(n = 5/group, **p<0.01 vs. all other groups). c, Ratio of kidney weight to total body weight 
(note body weights statistically indistinguishable as well, n=4/group). d, Example gross 
images with 1 cm scale of control vs. iNephPGC1α kidney. e, Renal mitochondrial DNA 
(mtDNA) copy number as described in Methods. f, Relative renal gene expression of PGC1α 
targets (Ndufs1, Cycs, Atp5o), partnering transcription factors (Nrf1), and the mitochondrial 
transcription factor, TFAM. Results analyzed by two-way ANOVA with p-value for 
genotype as noted. N=8/group. *p<0.05 vs. control after Bonferroni correction. g, Western 
analysis of kidney lysates for Transcription Factor A, Mitochondrial (TFAM)37 and loading 
control. h,i, Transmission EM of mitochondria sectioned perpendicular and parallel to long 
axis demonstrating normal morphology in iNephPGC1α mice (representative of n=4/group), 
scale bar 500 nm. j,k, Blinded scoring of tubular injury in cortex and outer stripe of outer 
medulla (n=8 control; 12 iNephPGC1α). Error bars SEM, *p<0.05, **p<0.01.
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Extended Data Fig 5. Renal protection in systemic inflammation conferred by renal tubular 
epithelial, but not endothelial, PGC1α
a, Serum creatinine 24 h after bacterial endotoxin injection (LPS O111:B4), n=9/group. b, 
Serum creatinine 24 h after bacterial endotoxin (LPS O111:B4) in endothelial-specific 
(VEC=VE-cadherin) PGC1α transgenic mice (VEC-tTA x TRE-PGC1α), n=5/group. Error 
bars SEM, *p < 0.05.
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Extended Data Fig 6. PGC1α-dependent de novo NAD biosynthesis and NAD-dependent 
accumulation of β-OHB and PGE2
a, Gene expression for de novo NAD biosynthetic pathway in renal tubular cells 48 h after 
control vs. PGC1α knockdown (n=3/group). The gene expression set corresponds to the 
eight transcripts whose abundance was measured in kidney homogenates in Figure 3. 
P=0.0001 by two-way ANOVA with Bonferroni-corrected comparisons as indicated. b, 
Correlation of renal Nam vs. renal NAD in mice treated with vehicle or different doses of 
Nam (100–400 mg/kg IP × 1). Arbitrary units on X- and Y-axes. c, Renal β-OHB 
concentrations in kidneys of mice following vehicle (Veh) vs. Nam treatment (400 mg/kg IP 
× 4 d) with and without IRI 24 h prior to tissue collection (n=5/group). P-value by two-way 
ANOVA. Dashed line indicates normal circulating concentration of β-OHB. d, Dosing for 
siRNA against HCAR2 in renal tubular cells. e, Dose-inhibition curve in renal tubular cells 
for PGE2 release following 24 h of mepenzolate bromide at the indicated concentrations 
(n=3 replicates per concentration).32–34 f,g Intracellular Nam and secreted β-OHB for renal 
tubular cells following treatment with Nam (1 μM for 24 h) with or without pre-treatment 
with the NAMPT inhibitor FK866 (10 nM, n=6/group). h, PGE2 in conditioned media of 
renal tubular cells after control vs. PGC1α knockdown and with and without exogenous β-
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OHB application (+, 5 mM, n=6/group, p values vs. control group). Error bars SEM, 
*p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001.
Extended Data Fig 7. Effects of PGC1α on renal metabolites and features of cisplatin 
nephrotoxicity
a–c, Relative renal NAD, β-OHB, and PGE2 concentrations in WT littermates vs. PGC1α−/− 
(KO) mice (n=6/group). d, Serum creatinine in genetic control mice for iNephPGC1α 24 h 
after IRI with vehicle vs. mepenzolate (MPN, 10 mg/kg IP) treatment (n=5/group). e, Serum 
creatinine in genetic control mice for iNephPGC1α 24 h after IRI with vehicle vs. 
indomethacin (INDO, 10 mg/kg IP) treatment (n=6/group). f, Transmission EM with 
cytochrome c oxidase enzyme histochemistry of proximal tubular cell 24 h following 
cisplatin exposure (25 mg/kg IP) demonstrating mitochondrial injury. Scale bar 500 nm. g, 
Relative renal Nam concentrations following cisplatin as in f. Error bars SEM, *p<0.05, 
**p<0.01, ***p<0.001.
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Extended Data Fig 8. Renal immunostaining for PGC1α declines in human chronic kidney 
disease
a–d, Low (a,b) and high-power (c,d) photomicrographs of PGC1α immunoreactivity 
(brown) in wildtype littermates (WT) and PGC1α−/− (KO) kidneys. Scale bars 100 and 50 
μm. e,f Representative results of peptide competition attenuating PGC1α immunoreactivity 
against human kidney (n=4) as described in Methods. g, Representative immunostaining 
(brown) for PGC1α in a renal biopsy with chronic kidney disease (CKD). Scale bar 50 μm. 
h, Results of scoring PGC1α immunostaining intensity (1=weakest, 4=strongest) in 
specimens with CKD by blinded operator. Each dot represents a unique specimen. Analyzed 
by Mann-Whitney.
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Extended Data Fig 9. Evidence for renal-tubular-epithelial-PGC1α-dependent reversible 
vascular relaxation
a, Serum creatinine in uninduced (−Dox) vs. induced (+Dox) iNephPGC1α mice (n = 8–10 
mice per group). b, Comparison of serum creatinine with degree of renal PGC1α expression, 
p<0.05. c,d Serial serum creatinines in iNephPGC1α mice vs. controls before PGC1α 
induction (OFF), after 4 weeks of PGC1α induction (ON), and after 4 weeks of washout 
(OFF), *p<0.05 by repeated measures ANOVA. e–g, Comparison of serum creatinine at 
different time points with renal artery flow in iNephPGC1α mice from d, p<0.05 when 
correlation coefficient r = −0.65. h–j, Comparison of resistive index with renal artery flow 
volume in iNephPGC1α mice from d, p<0.05 when correlation coefficient r = −0.80. k, 
Relative renal expression of VEGF and nitric oxide synthases 1 and 3 (n=6/group). 
Analyzed by two-way ANOVA with Bonferroni corrections. l, Circulating thyroxine levels 
in iNephPGC1α mice with and without gene induction (n=5/group) to rule out Pax8-related 
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thyrotoxicosis driving perfusion differences as previously described.44 m, Relative renal 
expression for VEGF in PGC1α−/− mice (KO) vs. WT littermates (n=6/group). Error bars 
SEM.
Extended Data Fig 10. 
Relative renal expression for NAMPT in wildtype mice before and 24 h after IRI (n=6/
group). Error bars SEM.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Niacinamide (Nam) supplementation restores normal post-ischemic response in 
PGC1α−/− mice
a, Pre-ischemic normal morphology and b, swollen mitochondria inside tubular cell 24h 
after ischemia-reperfusion injury (IRI). Scale bar 200nm. c, Renal di-/tri-acylglycerols 
(DAGs, TAGs) 24h following sham or IRI (n=6/group). P-value by ANOVA. d,e, Oil Red O 
(pink) for fat in normal and post-ischemic kidneys, scale bar 20μm. f, serum creatinine 
wildtype (WT) vs PGC1α−/− (KO) mice (basal, n=7/group; post-ischemia, n=18/group). g,h, 
Volcano plots of kidney metabolites from KO vs. WT or IRI vs. sham (univariate p<0.05 for 
colored dots, n=6/group). i, Serum creatinine in post-ischemic WT vs. KO mice treated with 
vehicle (Veh, n=5) vs. Nam (n=9). Error bars SEM, *p<0.05, **p<0.01.
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Figure 2. Metabolic protection in post-ischemic iNephPGC1α mice
a,b, Renal cytochrome c oxidase activity (brown), scale bar 500μm. c, Renal PGC1α and 
cytochrome c oxidase subunit IV. d, Survival curve following IRI (n=14 control; 24 
iNephPGC1α). Dashed line for sham-operated mice (n=10). e, Serial serum creatinines from 
mice in d analyzed by ANOVA. f,g, Renal artery pulse wave and color Doppler 24h after IRI 
representative of 6/group. h–k, Tubular injury in cortex and outer stripe of outer medulla 
(OSOM) 24h after IRI representative of 8/group. Scale bar 100μm. l–o, Oil red O (pink) for 
fat in iNephPGC1α mice and controls 24h after IRI representative of 8/group. Scale bars 
200μm (upper) and 50μm (lower). p, Renal Di-/tri-acylglycerols (DAGs, TAGs) in post-
ischemic iNephPGC1α mice vs. controls (n=6/group). q, Relative renal Nam 24h after IRI 
(n=6/group). Error bars SEM, *p<0.05.
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Figure 3. Nam induces β-OHB downstream of PGC1α to augment PGE2
a, Renal RNA sequencing 24h after IRI or sham operation in controls vs. iNephPGC1α mice 
with enumerated transcripts. b, Pathway analysis of 1160 transcripts unique to post-ischemic 
iNephPGC1α mice graphed by −log10[Benjamini-Hochberg-corrected p-value]. Dashed line 
at p<0.05. c, de novo NAD biosynthetic pathway adapted from KEGG (www.genome.jp/
kegg). Trp=tryptophan, Kyn=kynurenine, Am=amino, Na=nicotinate. d–f, Heatmaps 
(red=lower, blue=higher) of intrarenal expression for de novo pathway from KO vs. WT; 
24h after sham vs. IRI; and iNephPGC1α vs. controls (n=6/group). P-values by ANOVA. g, 
Relative renal Nam and NAD 4h after indicated Nam dose. P-value by ANOVA. h, 
Conditioned-media-PGE2 of renal tubular cells after HCAR2 knockdown with and without 
HCAR2 stimulation (+,niacin 10mM, n=6/group). i, PGE2 from renal cells following Nam 
(1μM for 24h) with and without NAMPT inhibitor FK866 (10nM, n=6/group). j–l, 
Intracellular NAD, conditioned-media beta-hydroxybutyrate (β-OHB), and conditioned-
media PGE2 in PGC1α knockdown cells (n=6/group). m–o, Relative renal NAD, β-OHB, 
and PGE2 in control vs. iNephPGC1α mice (n=6/group). *p<0.05, **p<0.01, ***p<0.001. 
p, Renal epithelial PGC1α coordinately upregulates de novo NAD biosynthesis, in the 
absence of which Nam is utilized through the NAMPT-salvage pathway to generate NAD. 
Consequently, β-OHB accumulates, which signals HCAR2 to induce PGE2. Error bars SEM.
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Figure 4. PGC1α effectors, Nam as therapy, and PGC1α in human AKI
a, Serum creatinine in iNephPGC1α mice 24h after IRI with vehicle vs. mepenzolate (MPN, 
10mg/kg IP) treatment (n=6/group). b, Serum creatinine in iNephPGC1α mice 24h after IRI 
with vehicle vs. indomethacin (INDO, 10mg/kg IP) treatment (n=6/group). c, Serial serum 
creatinines in mice receiving a single dose of Nam (400 mg/kg IP) 18h after the onset of 
reperfusion, i.e., with established AKI. Analyzed by ANOVA (n=5/group). d, Serial serum 
creatinines after cisplatin (25mg/kg IP administered on day 0) with or without Nam 
(400mg/kg IP on day −1 and day 0). Analyzed with Bonferroni-corrected ANOVA (n=5/
group). e, Relative renal Nam from d. f,g, Representative immunostaining (brown) for 
PGC1α from control human kidney and a renal biopsy for AKI. Scale bars 50μm. h, PGC1α 
immunostaining intensity (1=weakest, 4=strongest). Each dot represents a unique specimen. 
Analyzed by Mann-Whitney. Error bars SEM, *p<0.05, **p<0.01, ****p<0.0001.
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